Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · see citing works

Untitled work

(1977) · PubMed · Cited by 1,801 · see citing works

The new World Health Organization classification of lung tumours

Brambilla, E. M., Travis, W. D., Colby, T. V., CORRIN, B., & Shimosato, Y. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00275301 · Cited by 1,129 · see citing works

The New Lung Cancer Staging System

Detterbeck, F. C., Boffa, D. J., & Tanoue, L. T. (2009) · CHEST Journal · doi:10.1378/chest.08-0978 · Cited by 820 · see citing works

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · see citing works

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 617 · see citing works

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients

Yung, T., Chan, K. C. A., Mok, T. S. K., TONG, J. H. M., To, K., & Lo, Y. M. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2622 · Cited by 381 · see citing works

Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Gautschi, O. P., Bigosch, C., Huegli, B., Jermann, M., Marx, A., Chassé, E., Ratschiller, D., Weder, W., Joerger, M., Betticher, D. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.123 · Cited by 276 · see citing works

Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer

Bai, H., Mao, L., Wang, H. S., Zhao, J., Yang, L., An, T., Wang, X., Duan, C. J., Wu, N. M., Guo, Z. Q., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3930 · Cited by 268 · see citing works

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., & Kato, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00782.x · Cited by 251 · see citing works

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

Yatabe, Y., Matsuo, K., & Mitsudomi, T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3906 · Cited by 222 · see citing works

Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors

Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 218 · see citing works

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

Gow, C., Chang, Y., Hsu, Y.-C., Tsai, M.-F., Wu, C., Yu, C., Yang, J. C., Lee, Y., Yang, P., & Shih, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn679 · Cited by 211 · see citing works

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E. L., McCormack, R., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f98 · Cited by 209 · see citing works

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

Kimura, H., Suminoe, M., Kasahara, K., Sone, T., Araya, T., Tamori, S., Koizumi, F., Nishio, K., Miyamoto, K., Fujimura, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603949 · Cited by 200 · see citing works

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

Yoshida, K., Yatabe, Y., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Kosaka, T., Mitsudomi, T., & Hida, T. (2007) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30013-7 · Cited by 165 · see citing works

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

van Zandwijk, N., Mathy, A., Boerrigter, L., Ruijter, H. J., Tielen, I. H. G., de Jong, D., Baas, P., Burgers, S. A., & Nederlof, P. M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl323 · Cited by 146 · see citing works

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors

Italiano, A., Burel‐Vandenbos, F., Otto, J., Mouroux, J., Fontaine, D., Marcy, P. Y., Cardot‐Leccia, N., Thyss, A., & Pédeutour, F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl038 · Cited by 128 · see citing works

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

Sunaga, N., Tomizawa, Y., Yanagitani, N., Iijima, H., Kaira, K., Shimizu, K., Tanaka, S., Suga, T., Hisada, T., Ishizuka, T., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.01.025 · Cited by 127 · see citing works

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

Uramoto, H., & Mitsudomi, T. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603665 · Cited by 95 · see citing works

Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites

Bozzetti, C., Tiseo, M., Lagrasta, C. A., Nizzoli, R., Guazzi, A., Leonardi, F., Gasparro, D., Spiritelli, E., Rusca, M., Carbognani, P., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8ba2 · Cited by 62 · see citing works

Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer

Cohen, V., Agulnik, J. S., Jarry, J., Batist, G., Small, D. I., Kreisman, H., Tejada, N. A., Miller, W. H., & Chong, G. (2006) · Cancer · doi:10.1002/cncr.22331 · Cited by 61 · see citing works

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Chin, T. M., Quinlan, M. P., Singh, A., Sequist, L. V. D., Lynch, T. J., Haber, D. A., Sharma, S. V., & Settleman, J. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0093 · Cited by 53 · see citing works

Analysis of Cancer Mutation Signatures in Blood by a Novel Ultra-Sensitive Assay: Monitoring of Therapy or Recurrence in Non-Metastatic Breast Cancer

Chen, Z., Feng, J., Buzin, C. H., Liu, Q., Weiss, L. M., Kernstine, K. H., Somlo, G., & Sommer, S. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007220 · Cited by 47 · see citing works

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI

Huang, Z., Wang, Z., Bai, H., Wu, M., An, T., Zhao, J., Yang, L., Duan, J., Zhuo, M., Wang, Y., et al. (2012) · Thoracic Cancer · doi:10.1111/j.1759-7714.2012.00133.x · Cited by 42 · see citing works

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1829-7 · Cited by 39 · see citing works

An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial

Gridelli, C., Butts, C. A., Ciardiello, F., Feld, R. D., Gallo, C., & Perrone, F. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.037 · Cited by 32 · see citing works

High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

Morán, T., Paz-Ares, L. G., Isla, D., Cobo, M., Massutí, B., Insa, A., Queralt, C., Pradas, A., Tarón, M., & Rosell, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7505 · Cited by 13 · see citing works

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.

Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Tofanetti, F. R., Siggillino, A., Baldelli, E., Colella, R., Mameli, M. G., & Crinò, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7562 · Cited by 3 · see citing works

Liquid biopsy: monitoring cancer-genetics in the blood

Crowley, E. H., Nicolantonio, F. D., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,821 · see citing works

Biological and therapeutic impact of intratumor heterogeneity in cancer evolution

McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077 · see citing works

Artificial Intelligence in Cancer Research and Precision Medicine

Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0090 · Cited by 781 · see citing works

The emerging role of cell-free DNA as a molecular marker for cancer management

Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566 · see citing works

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer

Noronha, V., Patil, V., Joshi, A., Menon, N. S., Chougule, A., Mahajan, A., Janu, A., Purandare, N. C., Kumar, R., More, S. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 420 · see citing works

Heterogeneity in Lung Cancer

de Sousa, V. M. L., & Carvalho, L. (2018) · Pathobiology · doi:10.1159/000487440 · Cited by 369 · see citing works

Non-invasive decision support for NSCLC treatment using PET/CT radiomics

Mu, W., Jiang, L., Zhang, J., Shi, Y., Gray, J. E., Tunali, I., Gao, C., Sun, Y., Tian, J., Zhao, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19116-x · Cited by 289 · see citing works

Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art

Lee, G., Lee, H. Y., Park, H., Schiebler, M. L., van Beek, E. J. R., Ohno, Y., Seo, J. B., & Leung, A. N. C. (2016) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.09.005 · Cited by 277 · see citing works

Circulating Tumor DNA as Biomarkers for Cancer Detection

Han, X., Wang, J., & Sun, Y. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.12.004 · Cited by 241 · see citing works

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sánchez, J. M., Porta, R., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.257 · Cited by 239 · see citing works

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

Luo, J., Shen, L., & Zheng, D. (2014) · Scientific Reports · doi:10.1038/srep06269 · Cited by 212 · see citing works

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer

Zhu, G., Ye, X., Dong, Z., Lu, Y., Sun, Y., Liu, Y., McCormack, R., Gu, Y., & Liu, X. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.01.004 · Cited by 203 · see citing works

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

Qiu, M., Wang, J., Xu, Y., Ding, X., Li, M., Jiang, F., Xu, L., & Yin, R. H. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0895 · Cited by 190 · see citing works

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173 · see citing works

Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study.

Wang, S., Yu, H., Gan, Y., Wu, J. Z., Li, E.-C., Li, X., Cao, J., Zhu, Y., Wang, L., Deng, H., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00024-3 · Cited by 159 · see citing works

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

Weber, B., Meldgaard, P., Hager, H., Wu, L., Wei, W., Tsai, J., Khalil, A. A., Nexø, E., & Sørensen, B. S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-294 · Cited by 154 · see citing works

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., Xue, C., Zhang, J., Zhang, J., Ma, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085245 · Cited by 133 · see citing works

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

Cai, W., Lin, D., Wu, C., Li, X., Zhao, C., Zheng, L.-M., Chuai, S., Fei, K., Zhou, C., & Hirsch, F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8293 · Cited by 134 · see citing works

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 128 · see citing works

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study

Mazières, J., Brugger, W., Cappuzzo, F., Middel, P., Frosch, A., Bāra, I., Klingelschmitt, G., & Klughammer, B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.016 · Cited by 119 · see citing works

Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer

Li, Y., Li, Y., Yang, T., Wei, S., Wang, J., Wang, M., Wang, Y., Zhou, Q., Liu, H., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052093 · Cited by 115 · see citing works

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

Angulo, B., Conde, E., Suárez‐Gauthier, A., Plaza, C., Martínez, R., Redondo, P., Izquierdo, E., Rubio‐Viqueira, B., Paz-Ares, L. G., Hidalgo, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043842 · Cited by 101 · see citing works

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

Siena, S., Bianchi, A. S., García‐Carbonero, R., Karthaus, M., Smith, D. M., Tabernero, J. M., Cutsem, E. V., Guan, X., Boedigheimer, M. J., Ang, A. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 97 · see citing works

Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma

Choi, E.-R., Lee, H. Y., Jeong, J. Y., Choi, Y., Kim, J., Bae, J., Lee, K. S., & Shim, Y. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11693 · Cited by 91 · see citing works

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Zhong, W., Yang, X., Yan, H., Zhang, X., Su, J., Chen, Z., Liao, R.-Q., Nie, Q., Dong, S., Zhou, Q. H., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0151-3 · Cited by 92 · see citing works

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Bai, H., Wang, Z., Wang, Y., Zhuo, M., Zhou, Q., Duan, J., Yang, L., Wu, M., An, T., Zhao, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054170 · Cited by 89 · see citing works

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?

Kim, L., & Tsao, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00197013 · Cited by 87 · see citing works

Role of circulating-tumor DNA analysis in non-small cell lung cancer

Jiang, T., Ren, S., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.013 · Cited by 82 · see citing works

Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma

Xu, T., Kang, X., You, X., Dai, L. X., Tian, D., Yan, W., Yang, Y., Xiong, H., Liang, Z., Zhao, G., et al. (2017) · Theranostics · doi:10.7150/thno.16558 · Cited by 82 · see citing works

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

Yang, X., Zhuo, M., Ye, X., Bai, H., Wang, Z., Sun, Y., Zhao, J., An, T., Duan, J., Wu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8021 · Cited by 78 · see citing works

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 78 · see citing works

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Li, X., Ren, R., Ren, S., Chen, X., Cai, W., Zhou, F., Zhang, Y., Su, C., Zhao, C., Li, J., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.006 · Cited by 73 · see citing works

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations

Li, X., Cai, W., Yang, G., Su, C., Ren, S., Zhao, C., Hu, R., Chen, X., Gao, G., Guo, Z., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.006 · Cited by 66 · see citing works

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 65 · see citing works

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66 · see citing works

PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer

Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61 · see citing works

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer

Nie, K., Jia, Y., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2758-3 · Cited by 61 · see citing works

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Holleman, M. S., van Tinteren, H., Groen, H. J. M., Al, M., & Groot, C. A. U. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189438 · Cited by 62 · see citing works

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

Zhong, J., Li, L., Wang, Z., Bai, H., Gai, F., Duan, J., Zhao, J., Zhuo, M., Wang, Y., Wang, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.032 · Cited by 60 · see citing works

Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR

Ren, S., Su, C., Wang, Z., Li, J., Fan, L., Li, B., Li, X., Zhao, C., Wu, C., Hou, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28925 · Cited by 53 · see citing works

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

Qian, X., Liu, J., Sun, Y., Wang, M., HuaiDing, L., Luo, G., Liu, X., Xiong, C., Liu, J., Liu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8684 · Cited by 52 · see citing works

Fool’s gold, lost treasures, and the randomized clinical trial

Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51 · see citing works

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer

Dong, Z., Zhai, H.-R., Hou, Q., Su, J., Liu, S., Yan, H., Li, Y.-S., Chen, Z., Zhong, W., & Wu, Y.-L. L. C. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0150 · Cited by 50 · see citing works

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer

Wan, R., Wang, Z., Lee, J. J., Wang, S., Li, Q., Tang, F., Wang, J., Sun, Y. L., Bai, H., Wang, D., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.011 · Cited by 47 · see citing works

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43 · see citing works

Tumour biomarkers—Tracing the molecular function and clinical implication

Lin, J., Ma, L., Zhang, D., Gao, J., Jin, Y., Han, Z., & Lin, D. (2019) · Cell Proliferation · doi:10.1111/cpr.12589 · Cited by 42 · see citing works

Favorable Prognostic Impact in Loss of TP53 and PIK3CA Mutations after Neoadjuvant Chemotherapy in Breast Cancer

Jiang, Y., Yu, K., Bao, J., Peng, W.-T., & Shao, Z. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0092 · Cited by 40 · see citing works

Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression

Socinski, M. A., Villaruz, L. C., & Ross, J. S. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0285 · Cited by 40 · see citing works

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology

Roma, C., Esposito, C., Rachiglio, A. M., Pasquale, R., Iannaccone, A., Chicchinelli, N., Franco, R., Mancini, R., Pisconti, S., Luca, A. D., et al. (2013) · BioMed Research International · doi:10.1155/2013/385087 · Cited by 38 · see citing works

Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing

Li, W., Qiu, T., Guo, L., & Ying, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.014 · Cited by 38 · see citing works

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Guo, Q., Wang, L., Yu, W., Qiao, L., Zhao, M., Hu, X., Sun, Y., Ni, S., Xu, Y., & Lou, J. (2019) · Journal of Cancer · doi:10.7150/jca.31326 · Cited by 38 · see citing works

Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology

Ferté, C., Trister, A. D., Huang, E. S., Bot, B. M., Guinney, J., Commo, F., Sieberts, S. K., André, F., Besse, B., Soria, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3937 · Cited by 36 · see citing works

The emerging treatment landscape of advanced non-small cell lung cancer

Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36 · see citing works

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Tomonaga, N., Nakamura, Y., Yamaguchi, H., Ikeda, T., Mizoguchi, K., Motoshima, K., Doi, S., Nakatomi, K., Iida, T., Hayashi, T., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.005 · Cited by 35 · see citing works

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Kanda, S., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Kubota, K., Tamura, T., & Ohe, Y. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.016 · Cited by 34 · see citing works

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer

Hu, W., Yang, Y., Zhang, L., Yin, J., Huang, J., Huang, L., Gu, H., Jiang, G., & Fang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.980 · Cited by 30 · see citing works

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance.

Remón, J., & Majem, M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.14 · Cited by 30 · see citing works

Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma

Loh, K. P., Mondo, E. L., Hansen, E., Sievert, L., Fung, C., Sahasrabudhe, D. M., & Guancial, E. A. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.013 · Cited by 30 · see citing works

Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India

Veldore, V., Rao, R. M., Kakara, S., Pattanayak, S., Tejaswi, R., Sahoo, R., Venkataswamy, E., Prabhudesai, S., Krishnamoorthy, N., Tejaswini, B. N., et al. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117013 · Cited by 29 · see citing works

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Hollander, P., Amini, R., Ginman, B., Molin, D. L., Enblad, G., & Glimelius, I. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204870 · Cited by 29 · see citing works

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Hou, H., Yang, X., Zhang, J., Zhang, Z., Xu, X., Zhang, X., Zhang, C., Liu, D., Yan, W., Zhu, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14962-0 · Cited by 28 · see citing works

Autoimmune response to PARP and BRCA1/BRCA2 in cancer

Zhu, Q., Han, S.-X., Zhou, C.-Y., Cai, M.-J., Dai, L.-P., & Zhang, J.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3428 · Cited by 27 · see citing works

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02053-2 · Cited by 28 · see citing works

Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer

Ding, S., Song, X., Geng, X., Liu, L., Ma, H., Wang, X., Wei, L., Xie, L., & Song, X. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13178 · Cited by 27 · see citing works

Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer

Normanno, N., Pinto, C., Taddei, G., Gambacorta, M., Castiglione, F., Barberis, M. C. P., Clemente, C., & Marchetti, A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c2b08 · Cited by 26 · see citing works

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Asami, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.646 · Cited by 25 · see citing works

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

Kim, I. A., Lee, J. S., Kim, H. J., Kim, W. S., & Lee, K. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4691-0 · Cited by 25 · see citing works

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis

Zhang, Q., Dai, H.-H., Dong, H.-Y., Sun, C.-T., Yang, Z., & Han, J.-Q. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.011 · Cited by 25 · see citing works

Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial

Zhang, R., Pu, W., Zhang, S., Chen, L., Zhu, W., Li, X., Xing, C., & Li, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191756 · Cited by 25 · see citing works

Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

Wang, H., Zhang, M., Tang, W., Ma, J., Wei, B., Niu, Y., Zhang, G., Li, P., Yan, X., & Ma, Z. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450115 · Cited by 24 · see citing works

Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor TM Assay

Sisson, B., Uvalic, J., Kelly, K., Selvam, P., Hesse, A., Ananda, G., Chandok, H., Bergeron, D., Holinka, L., & Reddi, H. V. (2019) · Biomarker Insights · doi:10.1177/1177271919826545 · Cited by 24 · see citing works

GMILT: A Novel Transformer Network That Can Noninvasively Predict EGFR Mutation Status

Zhao, W., Chen, W., Li, G., Lei, D., Yang, J., Chen, Y.-J., Jiang, Y., Wu, J., Ni, B.-B., Sun, Y.-Q., et al. (2022) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2022.3190671 · Cited by 24 · see citing works

Intratumoral Heterogeneity in Lung Cancer

Lv, X., Mao, Z.-X., Sun, X.-J., & Liu, B.-J. (2023) · Cancers · doi:10.3390/cancers15102709 · Cited by 23 · see citing works

AI-based pipeline for early screening of lung cancer: integrating radiology, clinical, and genomics data

Batra, U., Nathany, S., Nath, S. K., Jose, J. T., Sharma, T., Preeti, P., Pasricha, S., Sharma, M., Arambam, N., Khanna, V., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100352 · Cited by 22 · see citing works

Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

Remón, J., Morán, T., Reguart, N., Majem, M., Carcereny, E., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.006 · Cited by 22 · see citing works

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)

Saad, N., Poudel, A., Basnet, A., & Gajra, A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100650 · Cited by 22 · see citing works

Target Therapy in Lung Cancer

Cafarotti, S., Lococo, F., Frösch, P., Zappa, F., & Dutly, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_6 · Cited by 21 · see citing works

Therapeutic bronchoscopy in the era of genotype directed lung cancer management

Mohan, A., Harris, K. N., Bowling, M., Brown, C., & Hohenforst‐Schmidt, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.14 · Cited by 21 · see citing works

Transfer learning–based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in lung adenocarcinoma

Shao, X., Ge, X., Gao, J., Niu, R., Shi, Y., Shao, X., Jiang, Z., Li, R., & Wang, Y. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01232-5 · Cited by 21 · see citing works

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

Marcq, M., Vallée, A., Bizieux, A., & Denis, M. G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000134 · Cited by 20 · see citing works

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

He, Y., Wang, Y., Boyle, T. A., Ren, S., Chan, D., Rivard, C. J., Li, X., Li, J., Zhou, C., & Hirsch, F. R. (2016) · Medical Science Monitor · doi:10.12659/msm.896607 · Cited by 20 · see citing works

Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas

Cai, Y., Dong, Y., Wu, H., Liu, Z.-C., Zhou, L.-J., Su, D., Chen, X.-J., Zhang, L., & Zhao, Y. (2016) · Scientific Reports · doi:10.1038/srep23755 · Cited by 20 · see citing works

Liquid biopsy for lung cancer immunotherapy (Review)

Cai, L., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10166 · Cited by 19 · see citing works

Investigating intratumour heterogeneity by single-cell sequencing

Ren, S., Qu, M., & Ying-hao, S. U. N. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.106 · Cited by 18 · see citing works

Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer

Wang, Z., Fu, S., Zhao, J., Zhao, W., Shen, Z., Wang, D., Duan, J., Bai, H., Wan, R., Yu, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.014 · Cited by 18 · see citing works

Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.

Liang, W., Zhang, Y., Kang, S., Pan, H., Shao, W., Deng, Q., Shi, X., Wang, W., & He, J. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.07.33 · Cited by 18 · see citing works

Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis

OuYang, P., Su, Z. Z., Mao, Y., Deng, W., & Xie, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079000 · Cited by 18 · see citing works

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Yang, Y., Zhang, B., Li, R., Liu, B., & Wang, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.4409 · Cited by 17 · see citing works

Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy

Shao, L., Zhang, B., He, C., Lin, B., Song, Z., Lou, G., Yu, X., & Zhang, Y. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131290 · Cited by 17 · see citing works

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Khatami, F., & Tavangar, S. M. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0334-x · Cited by 17 · see citing works

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Wang, Q., Gao, W., Gao, F., Jin, S., Qu, T., Lin, F., Zhang, C., Zhang, J., Zhang, Z., Chen, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08291-9 · Cited by 15 · see citing works

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Buffoni, L., Vavalà, T., & Novello, S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0429-x · Cited by 17 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non–Small-Cell Lung Cancer

Novello, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7587 · Cited by 17 · see citing works

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Tseng, J., Yang, T., Chen, K., Hsu, K.-H., Yu, C., Liao, W., Tsai, C., Tsai, M.-H., Yu, S., Su, K., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s62639 · Cited by 16 · see citing works

Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803)

Yamada, K., Takayama, K., Kawakami, S., Saruwatari, K., Morinaga, R., Harada, T., Sueoka‐Aragane, N., Nagata, S., Kishimoto, J., Nakanishi, Y., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt056 · Cited by 16 · see citing works

Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer

Li, H., Zhang, X., Cao, J., Su, P., Lian, J., Song, X., Yang, W., Han, S., Xi, Y., & Wang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3653-2 · Cited by 16 · see citing works

Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer

Wang, Y., Duan, J., Chen, H., Bai, H., An, T., Zhao, J., Wang, Z., Zhuo, M., Wang, S., & Wang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.5740 · Cited by 16 · see citing works

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Kleeberg, U. R., Fink, M. K., Tessen, H.-W., Nennecke, A., Hentschel, S., & Bartels, S. (2013) · Oncology Research and Treatment · doi:10.1159/000351253 · Cited by 16 · see citing works

The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer

Zhao, J., Wang, X., Xue, L., Xu, N., Ye, X., Zeng, H., Lu, S., Huang, J., Akesu, S., Xu, C., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1618-2 · Cited by 15 · see citing works

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

Masuda, T., Imai, H., Kuwako, T., Miura, Y., Yoshino, R., Kaira, K., Shimizu, K., Sunaga, N., Tomizawa, Y., Ishihara, S., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1297-8 · Cited by 16 · see citing works

Effect of chemotherapy on EGFR mutation status in Chinese non-small cell lung cancer patients.

Wang, J., Bai, H., Zhao, J., Wang, Z., Zhuo, M., Wu, M., Duan, J., & Wang, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e18031 · Cited by 2 · see citing works

Influence of chemotherapy on EGFR mutation status.

Luo, Y., & Chen, Y. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.12 · Cited by 12 · see citing works

Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

Wang, J., Chen, K., Bai, H., Zhao, J., Wang, Z., Zhuo, M., An, T., Duan, J., Yang, L., Wu, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7031 · Cited by 4 · see citing works

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Shi, X., Huang, F., Chen, A. M., Wu, Z., Huang, Q., Liang, Y., Zhou, Q., Mo, H., Li, X., & Zhang, J. (2017) · Open Journal of Genetics · doi:10.4236/ojgen.2017.74010 · Cited by 1 · see citing works

Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

Hua, B., Zhao, J., Wang, S. H., Yang, L., Duan, J. C., Wu, M. N., & Wang, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8099 · Cited by 1 · see citing works